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The SANAD II study of the effectiveness and cost-effectiveness 
of levetiracetam, zonisamide, or lamotrigine for newly 
diagnosed focal epilepsy: an open-label, non-inferiority, 
multicentre, phase 4, randomised controlled trial
Anthony Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin Plumpton, 
Dyfrig A Hughes, Paula Williamson, Gus A Baker, Silviya Balabanova, Claire Taylor, Richard Brown, Dan Hindley, Stephen Howell, Melissa Maguire, 
Rajiv Mohanraj, Philip E Smith, on behalf of the SANAD II collaborators*
Summary
Background Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is 
uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of 
clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness 
of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy.
Methods This randomised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as 
first-line treatment for patients with newly diagnosed focal epilepsy. Adult and paediatric neurology services across 
the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked focal 
seizures. Participants were randomly allocated (1:1:1) using a minimisation programme with a random element 
utilising factor to receive lamotrigine, levetiracetam, or zonisamide. Participants and investigators were not masked 
and were aware of treatment allocation. SANAD II was designed to assess non-inferiority of both levetiracetam and 
zonisamide to lamotrigine for the primary outcome of time to 12-month remission. Anti-seizure medications were 
taken orally and for participants aged 12 years or older the initial advised maintenance doses were lamotrigine 
50 mg (morning) and 100 mg (evening), levetiracetam 500 mg twice per day, and zonisamide 100 mg twice per day. 
For children aged between 5 and 12 years the initial daily maintenance doses advised were lamotrigine 1·5 mg/kg 
twice per day, levetiracetam 20 mg/kg twice per day, and zonisamide 2·5 mg/kg twice per day. All participants were 
included in the intention-to-treat (ITT) analysis. The per-protocol (PP) analysis excluded participants with major 
protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analysis included all 
participants who received one dose of any study drug. The non-inferiority limit was a hazard ratio (HR) of 1·329, 
which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on 
lamotrigine. The trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64).
Findings 990 participants were recruited between May 2, 2013, and June 20, 2017, and followed up for a further 
2 years. Patients were randomly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328). 
The ITT analysis included all participants and the PP analysis included 324 participants randomly assigned to 
lamotrigine, 320 participants randomly assigned to levetiracetam, and 315 participants randomly assigned to 
zonisamide. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month 
remission versus lamotrigine (HR 1·18; 97·5% CI 0·95–1·47) but zonisamide did meet the criteria for non-inferiority 
in the ITT analysis versus lamotrigine (1·03; 0·83–1·28). The PP analysis showed that 12-month remission was 
superior with lamotrigine than both levetiracetam (HR 1·32 [97·5% CI 1·05 to 1·66]) and zonisamide (HR 1·37 
[1·08–1·73]). There were 37 deaths during the trial. Adverse reactions were reported by 108 (33%) participants who 
started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) par ticipants who started 
zonisamide. Lamotrigine was superior in the cost-utility analysis, with a higher net health benefit of 1·403 QALYs 
(97·5% central range 1·319–1·458) compared with 1·222 (1·110–1·283) for levetiracetam and 1·232 (1·112, 1·307) for 
zonisamide at a cost-effectiveness threshold of £20 000 per QALY. Cost-effectiveness was based on differences between 
treatment groups in costs and QALYs.
Interpretation These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients 
with focal epilepsy. Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the 
standard treatment in future trials.
Funding National Institute for Health Research Health Technology Assessment programme.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Epilepsy is a common condition with a prevalence of 
0·5–1% and lifetime incidence of up to 5%.1,2 Epilepsy is 
a complex disorder with many seizure types and causes. 
It is uniquely stigmatising and negatively affects quality 
of life (QOL), education, and employment prospects.3,4 
Anti-seizure medications are the mainstay of treatment 
and approximately 70% of people with epilepsy will 
achieve a remission from seizures, half of whom may be 
able to stop treatment without a seizure recurrence.
Around two-thirds of people with epilepsy have focal 
epilepsy; seizures that start in a neuronal network limited 
to one cerebral hemisphere. Seizure types include focal 
aware seizures (previously called simple partial seizures), 
focal seizures with impaired awareness (previously called 
complex partial seizures), and focal to bilateral tonic-
clonic seizures (previously called secondarily generalised 
tonic clonic seizures).5–7 Focal epilepsy can start at any 
age, and the incidence distribution is U shaped, with 
higher incidence in young and elderly people. Because of 
ageing populations, in many countries the incidence of 
focal epilepsy is higher in older people than in younger 
people.2
Although focal epilepsies can be classified according to 
site of seizure onset and cause, there is no evidence 
to suggest that one syndrome or cause responds better 
to one specific treatment than to another.8 The drug 
manage ment is therefore generally similar whatever the 
cause or syndrome. Guidelines typically recommend 
lamotrigine or carbamazepine as first-line treatment,9 
in part informed by the first standard and new 
antiepileptic drug trial (SANAD I),10 which identified 
lamotrigine as non-inferior to carbamazepine for time to 
12-month remission and superior to carbamazepine, 
gabapentin, oxcarbazepine, and topiramate for time to 
treatment failure.
Since the publication of SANAD I, several newer 
treatments have become available, including levetiracetam 
and zonisamide. Levetiracetam is a commonly prescribed 
anti-seizure medication with evidence of efficacy as 
monotherapy in patients with focal epilepsy based on 
finding non-inferiority compared with carbamazepine 
for 6-month seizure remission and similar tolerability 
in a regulatory trial11 that did not assess longer term 
effectiveness. A second open-label trial12 compared 
levetiracetam with physicians’ choice of carbamazepine or 
Research in context
Evidence before this study
At the time of the design of this trial (SANAD II) lamotrigine had 
been identified as a first-line treatment for patients with newly 
diagnosed focal epilepsy based in part on results of the first 
SANAD trial (published in 2007), which found lamotrigine to be 
non-inferior to carbamazepine for seizure remission but 
significantly less likely to fail as it is better tolerated. Lamotrigine 
was also found to be more clinically effective than gabapentin or 
topiramate and was also identified as a cost-effective 
alternative. Lamotrigine was therefore selected as the standard 
treatment in SANAD II.
Levetiracetam and zonisamide had been licensed for use as 
monotherapy in patients with focal epilepsy on the basis of 
non-inferiority regulatory trials in which they had been 
compared with carbamazepine. The primary outcome in those 
trials was 6-month seizure freedom, which is too short a 
timeframe to assess clinical effectiveness in a long-term 
condition such as epilepsy. Consequently, the longer term 
clinical effectiveness and cost-effectiveness of levetiracetam and 
zonisamide were unknown. This knowledge gap is reflected in 
the National Institute for Health and Care Excellence epilepsy 
guidelines, which do not recommend either drug as a first-line 
treatment. Nonetheless, levetiracetam in particular has been 
increasingly prescribed in clinical practice on the basis of 
assumptions about its ease of use, tolerability, and efficacy.
A Cochrane review and individual participant data network 
meta-analysis that included data from SANAD I found that, 
compared with carbamazepine, levetiracetam was inferior for 
time to 12-month remission and no significant difference was 
found compared with zonisamide. For time to treatment 
failure, levetiracetam was found to be superior to 
carbamazepine, but no difference was found between 
carbamazepine and zonisamide.
Added value of this study
To the best of our knowledge, this study is the first randomised 
controlled trial to assess the longer term clinical effectiveness 
and cost-effectiveness of levetiracetam and zonisamide as 
first-line treatments for patients with newly diagnosed focal 
epilepsy. The study is pragmatic in design and recruited a cohort 
of participants older than 5 years from routine UK National 
Health Service clinics, and the results are relevant to every day 
clinical practice.
Levetiracetam did not meet our definition of non-inferiority 
for time to 12-month remission compared with lamotrigine, 
and it was inferior for time to treatment failure. Zonisamide did 
meet our definition of non-inferiority for time to 12-month 
remission but it too was inferior for time to treatment failure. 
Neither levetiracetam or zonisamide were found to be 
cost-effective alternatives.
Implications of all the available evidence
For people with focal epilepsy, there is evidence that both 
levetiracetam and zonisamide have efficacy when used as 
monotherapy. However, the evidence does not support their 
use as first-line treatments. Our results support the continued 
use of lamorigine as first-line treatment for patients with focal 
epilepsy and its use as a standard comparator in future 
comparative trials.
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valproate, and it showed no significant difference between 
carbamazepine and levetiracetam for time to first seizure 
and time to treatment failure. However, that trial12 had a 
maximum follow-up of 12 months and therefore could 
not assess longer term outcomes needed to inform policy. 
In the 2012 NICE epilepsy guideline,9 levetiracetam was 
not recommended as a first-line treatment on the basis 
of an analysis indicating that it was not cost-effective. 
However, levetiracetam has since become available in 
generic form and is widely prescribed.
Zonisamide has been available for many years in 
Japan13 and southeast Asia. Its licence for use as a mono-
therapy is also based on a regulatory study14 showing 
non-inferiority to carbamazepine for 6-month seizure 
remission rates. The longer term comparative clinical 
and cost-effectiveness of zonisamide is unknown.
The aim of SANAD II was to assess the longer 
term clinical effectiveness and cost-effectiveness of 
levetiracetam and zonisamide compared with lamotrigine 
in people with newly diagnosed focal epilepsy.
Methods
Study design and participants
SANAD-II was a phase 4, multicentre, non-inferiority, 
open-label, randomised controlled trial that was run in 
65 UK National Health Service (NHS) adult neurology 
and paediatric services. Participants were eligible for 
recruitment if they were aged 5 years or older (there 
was no upper age limit), had a history of at least 
two unprovoked epileptic seizures requiring anti-seizure 
medication, their clinical diagnosis was one of focal 
epilepsy with or without an electroencephalogram, 
and they had never been treated with an anti-seizure 
medication except for emergency treatment in the 
previous 2 weeks. Exclusion criteria included patients 
with provoked or acute symptomatic seizures only, 
patients currently taking anti-seizure medication, and 
known progressive neurological disease (eg, brain 
tumour). Epileptic seizures and syndromes were classi-
fied according to International League Against Epilepsy 
classifications.5,6 SANAD II was granted ethics approval 
from the North West-Liverpool East Research Ethics 
Committee (Ref 12/NW/0361) on June 7, 2012.
Randomisation and masking
After providing consent, participants were randomly 
allocated (1:1:1) to receive either lamotrigine, levetiracetam, 
or zonisamide. We used a secure, centrally controlled, 
24-h web-based facility to implement a minimisation 
program with random element utilising factors, which 
were not made known to reduce the risk of predicting 
allocation. These factors were centre, sex (ie, male or 
female), and number of previous seizures (ie, 2, 3–5, 6+). 
Recruiting clinicians were required to initiate trial 
treatment within 7 days of randomisation. Participants 
and investigators were not masked and were all aware of 
treatment allocation.
Procedures
SANAD II was an open-label trial. Trial treatments were 
prescribed as per routine NHS practice and dispensed 
by hospital and community pharmacies, and clinicians 
prescribed the formulation they considered most 
appropriate. The trial protocol provided guidance on 
initial drug titration and maintenance doses based on 
routine practice, although clinicians were able to tailor 
these as appropriate. All anti-seizure medications were 
taken orally. For participants aged 12 years or more, the 
initial advised maintenance doses were lamotrigine 
(50 mg in the morning and 100 mg in the evening), 
levetiracetam (500 mg twice per day), and zonisamide 
(100 mg twice per day). For children aged 5–12 years, the 
initial daily maintenance doses advised were lamotrigine 
(1·5 mg/kg twice per day), levetiracetam (20 mg/kg twice 
per day), and zonisamide (2·5 mg/kg twice per day). 
Subsequent dose and treatment changes at follow-up 
visits were done following routine clinical practice 
according to treatment response and adverse effects.
We aimed to complete recruitment over a 4·5 year 
period but a 12-month extension was required to meet 
the sample size target, after which the trial cohort was 
followed up for a further 2 years, allowing a minimum 
follow up of 2 years and maximum of 7·5 years. Patients 
were followed up according to clinical need, and 
minimum trial visits were expected at 3, 6, and 12 months, 
and annually thereafter. At visits, data were collected for 
seizure type and frequency, anti-seizure medication, and 
adverse reactions. Participants continued in follow-up 
whether they were still taking their allocated treatment or 
not. For participants lost to hospital follow-up, outcome 
data were sought from their general practitioner.
For adults, QOL outcomes were assessed using 
subscales of the quality of life in newly diagnosed epilepsy 
battery (NEWQOL) and the Impact of Epilepsy Scale.15 
For children and adolescents aged <16 years, QOL 
assessment involved both patient and parent-based mea-
sures: children aged 8–15 years completed a generic health 
status measure validated for use in epilepsy, the KINDL;16 
and the epilepsy impact and attitude to epilepsy subscales 
of the Quality of Life in Epilepsy Inventory for Adolescents 
(QOLIE-AD).17 Parents of all children completed proxy 
QOL questionnaires. QOL question naires were completed 
at baseline and annually thereafter. Adults and parents 
also completed a subset of QOL measures at 3 months 
and 6 months.
Adult and adolescent participants were asked to 
complete the EQ-5D-3L and the EuroQol visual analogue 
scale (EQ-VAS); participants aged 8–15 completed the 
EQ-VAS and self-reported youth EQ-5D-3L-Y, or if not 
available, proxy EQ-5D-3L, completed by a parent or carer. 
For participants aged 5–7 years, only proxy questionnaires 
were administered. Participants’ resource-use associated 
with secondary care (ie, inpatient, outpatient, and accident 
and emergency), other health-care and social services (ie, 
primary care and community services), and medicines 
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were measured using routine hospital episode statistics, 
resource-use questionnaires,18 and case report form 
records. Resource-use was valued in monetary terms 
(measured in pounds sterling using national unit costs for 
2019–20) using national unit costs.19–22
Outcomes
The primary outcome was time to 12-month remission 
from seizures, calculated as days from randomisation to 
the first date at which a period of 12 months had elapsed 
without the patient having any seizures. The secondary 
seizure outcomes were time to 24-month remission and 
time to first seizure. There were three secondary outcomes 
for treatment failure: (1) time to treatment failure overall, 
defined as days from randomisation to a decision to 
withdraw the randomised drug, or to add a new anti-
seizure medication because of inadequate seizure control 
or unacceptable adverse reactions; (2) time to treatment 
failure due to inadequate seizure control; and (3) time to 
treatment failure due to unacceptable adverse reactions. 
The other secondary outcomes were adverse reactions, 
QOL, and health economic outcomes based on incremental 
costs and quality-adjusted life-years (QALYs).
Statistical analysis
SANAD-II was designed to detect non-inferiority of 
both levetiracetam and zonisamide compared with 
lamotrigine for the primary outcome of time to 12-month 
remis sion. The International League Against Epilepsy 
Commission on Antiepileptic Drugs defined limits 
of equivalence of ±10% for the primary outcome in 
antiepileptic drug monotherapy studies.23 Calculations 
were informed by the SANAD I study,9 which estimated 
the 12-month remission-free probability (at 24 months) 
of 0·43 (and an exponential hazard rate of 0·0352) 
for lamotrigine. Two primary comparisons were of 
interest (levetiracetam vs lamotrigine, and zonisamide vs 
lamotrigine), therefore the one-sided significance level 
was divided by two (one-side alpha of 0·0125). Assuming 
a 10% absolute difference in survival probability, the 
non-inferiority margin on the hazard ratio (HR) scale 
was ln(0·43)/ln(0·53)=1·329. Therefore, assuming a 
HR of 1 and 80% power with a one-sided alpha of 0·025, 
330 patients were required in each of three treatment 
groups, allowing for 5% losses to follow-up, as occurred 
in SANAD I (990 total patients).
Primary analyses were done on an intention-to-treat 
(ITT) basis. We used a 0·025 level of significance and 
97·5% CIs for analysis of the primary outcome because 
of the two prespecified comparisons. All secondary 
outcomes were analysed using a 0·05 level of significance 
and 95% CIs. The statistical and health economic 
analysis plans were developed before doing the final ana-
lyses and are available in appendix 1 and appendix 2. 
Analyses were done using SAS software (version 9.4; 
SAS Institute, Cary, NC, USA). Completeness of follow-
up statistics were calculated as the total number of days 
follow-up for all participants as a percentage of the total 
potential number of days follow-up.24
Time to event outcomes were summarised by Kaplan-
Meier curves for each treatment group and Cox 
pro portional hazards regression models explored using 
two different models: (1) the primary analysis, including 
the treatment effect only; (2) including the treatment 
together with gender (ie, male or female), number of 
seizures before randomisation (ie, 2, 3–5, 6+); and 
random effects for centre. The assumption of pro-
portional hazards was investigated by examining 
Schoenfeld residual plots and incorporating time-
dependent covariates in all models. If the assumption of 
proportional hazards was not valid, an additional Cox 
model with time-dependent covariates was used. For 
the primary outcome (ie, 12-month remis sion) non-
inferiority hypothesis, we present 97·5% CIs, in which 
the upper limit of the 97·5% CI needed to be less than 
1·329 to conclude non-inferiority. All other treatment 
effects are presented as a HR with a two-sided 95% CI of 
lamotrigine compared with levetiracetam or zonisamide.
A per-protocol (PP) analysis of the primary outcome was 
also done using the Fine and Gray model,18 with 
treatment failure included as a competing risk, and 
censoring participants with drug failure before achieving 
remission. This analysis excluded participants with major 
protocol deviations, participants subsequently given an 
alternative diagnosis to epilepsy, and participants who did 
not receive the drug at all.
For time to treatment failure, a competing risks 
analysis, using the Fine and Gray model,18 was done to 
assess the two main reasons for treatment failure (ie, 
inadequate seizure control and unacceptable adverse 
reactions).19 Cumulative incidence curves are presented 
for each treatment group.
The difference in QOL measures between treatment 
groups was estimated for each population (ie, children, 
adults, and parent-carers) and for each outcome applicable 
within that population by fitting a repeated measures 
random effects model with a baseline QOL variable, 
treatment group, and time in days using spatial-power 
covariance structure for repeated measures and unstruc-
tured covariance for the random effect. QALYs were 
calculated on the basis of the area under the curve of 
utility data measured using the EuroQol 5-dimension 
3-level (EQ-5D-3L) questionnaire, and applying the UK 
tariff scores.17
Analysis sets for the summary of adverse reactions 
included all patients who received any dose of a study 
drug. All adverse reactions and serious adverse reactions 
were coded using the MedDRA dictionary. The number 
(and percentage) of patients experiencing each reaction 
and the number (and percentage) of occurrences of each 
reaction are presented with no formal statistical testing 
undertaken.
Interim monitoring was done by an independent data 
safety and monitoring committee, meeting approximately 
See Online for appendix 1
See Online for appendix 2
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annually. This process included analyses of the primary 
outcome and five of the secondary outcomes (all using 
the Haybittle-Peto approach).
QALYs were calculated on the basis of the area under 
the curve of utility data measured using the EuroQol 
5-dimension 3-level (EQ-5D-3L) questionnaire, and 
applying the UK tariff scores.17
Health economic evaluation
The economic analysis (appendix 2) adopted the costing 
perspective of the NHS and personal social services and 
was done using data up to 24-months of follow-up and in 
accordance with the NICE guidelines for the methods of 
technology appraisal.20 Missing cost and QALY data 
were imputed using multiple imputation with chained 
equations.21 Based on the imputed data, differences 
between treatment groups in total costs and QALYs were 
compared with reference to bootstrapped central ranges, 
based on 10 000 replications. In the base-case analysis, 
total costs and QALYs (year 2 discounted at 3·5%) 
were adjusted using linear regressions25 for treatment 
allocation, baseline costs or utility, age, sex, and epilepsy 
classification, with centre as random effects. Incremental 
costs and QALYs were estimated to identify dominance, 
and calculate the incremental net health benefit as the 
difference in QALYs between treatments, minus the 
difference in costs multiplied by the cost-effectiveness 
threshold (ie, £20 000 per QALY).20 The joint uncertainty 
in incremental costs and QALYs were expressed in terms 
of the probability of each treatment being cost-effective at 
this threshold. Sensitivity analyses comprised alternative 
discount rates, use of complete cases, PP cohort, QALYs 
based on the NEWQOL-6D26 and EQ-VAS, and were 
based on unadjusted analyses. A subgroup analysis 
considered cost-effectiveness in children, adults, and 
adolescents aged 16 years or more at the point of random 
assignment.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
The first participant was randomly assigned on 
May 2, 2013, and the last participant was randomly 
assigned on June 20, 2017, after which every effort was 
made to follow the trial cohort for a further 2 years; the 
last participant follow-up visit was on October 17, 2019. 
65 UK centres recruited between one and 130 patients 
each, and randomly assigned a total of 990 participants, 
330 to start treat ment with lamotrigine, 332 to start 
treatment with levetiracetam, and 328 to start treatment 
with zonisamide (figure 1). Baseline characteristics were 
well balanced across treatment groups (table 1). The 
mean age of participants was 39·3 years (SD 21·2), and 
177 (17·9%) of 990 participants were younger than 
18 years.
There was a predominance of male participants 
(561 participants; 57%); 45 (5%) had a learning disability, 
163 (16%) had a previous or current neurological 
disorder, 107 (11%) had a first degree relative with 
epilepsy, 44 (4%) had a history of febrile convulsions. 
Moreover, 355 (36%) participants were classified with 
temporal lobe epilepsy, 62 (6%) had frontal lobe epilepsy, 
21 (2%) had occipital lobe epilepsy, 20 (2%) had parietal 
lobe epilepsy, and 499 (50%) had focal epilepsy localisa-
tion not specified. The median number of seizures 
Figure 1: Trial profile
Data on non-randomised patients were not collected. ITT=intention-to-treat.
330 allocated to receive lamotrigine 
330 included in ITT analysis
990 patients randomly assigned
2 did not receive allocated
   intervention
6 excluded from 
    per-protocol analysis 
    4 not epilepsy
    2 major treatment 
       protocol deviation
 
 
332 allocated to receive levetiracetam 328 allocated to receive zonisamide
332 included in ITT analysis
2 did not receive allocated
   intervention
12 excluded from 
      per-protocol analysis 
      10 not epilepsy
        2 major treatment
            protocol deviation
 
 
328 included in ITT analysis
324 patients included in per-protocol
         analysis
320 patients included in per-protocol
         analysis
315 patients included in per-protocol
        analysis
10 did not receive allocated
      intervention
13 excluded from 
      per-protocol analysis 
        2 not epilepsy
      11 major treatment
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before randomisation was 6 (IQR 3–24) and participants 
were randomly assigned a median of 13 days (3–36) after 
their most recent seizure.
The median (IQR) number of days of follow-up 
was 462·5 (365–777) for lamotrigine, 449·5 (365–824) for 
levetiracetam, and 447 (365–730) for zonisamide, with 
completeness of follow-up statistics for the primary 
outcome of 77% for lamotrigine, 78% for levetiracetam, 
and 76% for zonisamide.
Levetiracetam did not meet our definition of non-
inferiority to lamotrigine as the 97·5% CI for the HR (1·18 
[97·5% CI 0·95 to 1·47] unadjusted, 1·13 [0·91 to 1·41] 
adjusted]) included the pre-defined non-inferiority 
margin of 1·329. Consequently, we were unable to 
exclude the possibility of an important clinical difference 
between levetiracetam and lamotrigine. Zonisamide did 
meet our definition of non-inferiority to lamotrigine HR 
(1·03 [0·83 to 1·28] unadjusted, 1·01 [0·81 to 1·26] 
adjusted). There was no evidence of violation of the 
assumption of proportional hazards (p=0·90). Annual 
differences in annual 12-month remission probabilities, 
for example, that at 2 years follow-up we estimated that 
5% fewer participants had a remission on levetiracetam 
compared with lamotrigine (95% CI –13 to 3) and 
1% fewer on zonisamide compared with lamotrigine 
(–9 to 7), are shown in appendix 3 (p 2). The Kaplan-Meier 
estimates of the median time to achieve 12-month 
remission were 516 days (95% CI 457–577) for lamotrigine, 
588 days (472–706) for levetiracetam, and 530 days 
(453–601) for zonisamide (figure 2).
The PP analyses (using the Fine and Gray model) for 
time to 12-month remission (appendix 3 p 3) excluded 
Lamotrigine (n=330) Levetiracetam (n=332) Zonisamide (n=328) Total (n=990)
Age, years
Mean (SD; range) 40·1 (21·7; 5·1–91·9) 37·8 (20·1; 5·0–87·6) 39·9 (21·6; 5·0–89·1) 39·3 (21·2; 5·0–91·9)
Gender
Male 186 (56%) 190 (57%) 185 (56%) 561 (57%)
Female 144 (44%) 142 (43%) 143 (44%) 429 (43%)
History
Learning disability 15 (5%) 16 (5%) 14 (4%) 45 (5%)
Febrile convulsions 10 (3%) 19 (6%) 15 (5%) 44 (4%)
Acute symptomatic seizures 6 (2%) 9 (3%) 4 (1%) 19 (2%)
History of epilepsy in primary relatives 32 (10%) 35 (11%) 40 (12%) 107 (11%)
Neurological deficit 12 (4%) 20 (6%) 12 (4%) 44 (4%)
Previous or current neurological disorder
Any previous or current neurological disorder 57 (17%) 55 (17%) 51 (16%) 163 ( 16%)
Stroke or cerebrovascular 17 (5%) 16 (5%) 14 (4%) 47 (5%)
Cerebral haemorrhage 2 (1%) 5 (2%) 7 (2%) 14 (1%)
Intracranial surgery 4 (1%) 6 (2%) 10 (3%) 20 (2%)
Head injury 4 (1%) 7 (2%) 7 (2%) 18 (2%)
Meningitis or encephalitis 6 (2%) 5 (2%) 6 (2%) 17 (2%)
Cortical dysplasia or developmental anomaly 1 (<1%) 3 (1%) 0 4 (<1%)
Other 27 (8%) 24 (7%) 18 (5%) 69 (7%)
Epilepsy syndrome
Self-limiting childhood epilepsy with centro-
temporal spikes
9 (3%) 15 (5%) 10 (3%) 34 (3%)
Childhood epilepsy with occipital paroxysms 0 1 (<1%) 0 1 (<1%)
Temporal lobe 134 (41%) 110 (33%) 111 (34%) 355 (36%)
Frontal lobe 21 (6%) 21 (6%) 20 (6%) 62 (6%)
Parietal lobe 7 (2%) 8 (2%) 5 (2%) 20 (2%)
Occipital lobe 7 (2%) 12 (4%) 2 (1%) 21 (2%)
Focal epilepsy localisation not specified 152 (46%) 165 (50%) 182 (55%) 499 (50%)
Other epilepsy syndrome 3 (1%) 1 (<1%) 1 (<1%) 5 (1%)
Seizure history (median, IQR)
Total number of seizures reported 6 (3–29) 6 (3–22) 6 (3–23) 6 (3–24)
Days since first seizure 333 (110–1090) 318 (119–985) 328 (120–1097) 327 (114–1035)
Days since most recent seizure 13 (3–41) 13 (3–35) 11 (3–34) 13 (3–36)
Data are n (%), median (IQR), or mean (SD).
Table 1: Baseline characteristics of the patients
See Online for appendix 3
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patients with major protocol deviations (15 participants; 
1·5%) and patients later diagnosed as not meeting 
the diagnosis of epilepsy (16 participants; 1·6%), and 
accounted for treatment failures before achieving 
12-month remission (ie, 78 [24%] participants in 
the lamotrigine group, 177 [35%] participants in the 
levetiracetam group, and 127 [39%] participants in the 
zonisamide group) in a competing risks analysis. Results 
from the per-protocol analysis showed that the 12-month 
remission was superior with lamotrigine than both with 
levetiracetam (HR 1·32 [97·5% CI 1·05 to 1·66]) and with 
zonisamide (HR 1·37 [1·08–1·73]); although this trial was 
powered for non-inferiority, it was also designed to show 
superiority.
No significant difference was found in time to 
24-month remission (using ITT analysis) for lamotrigine 
versus levetiracetam (HR 1·04 [95% CI 0·81–1·33]) or 
for lamotrigine versus zonisamide (0·96 [0·75–1·23]) 
(appendix 3 p 4). No significant difference was found in 
time to first seizure (using ITT analysis) for lamotrigine 
versus levetiracetam (HR 1·07 [95% CI 0·89–1·29]) 
or lamotrigine versus zonisamide (1·04 [0·86–1·25]; 
appendix 3 p 5). The analysis of overall time to treatment 
failure for any reason (figure 3) found lamotrigine to be 
significantly less likely to fail than levetiracetam (0·60 
[0·46–0·77]) or than zonisamide (0·46 [0·36–0·60]), with 
no evidence against an assumption of proportional 
hazards (p=0·77). Annual treatment failure rates and 
differences in failure rates between lamotrigine and both 
levetiracetam and zonisamide are shown in appendix 3 
(p 6). Com pared with lamotrigine, there were 16% 
(95% CI 9–23) more treatment failures on levetiracetam 
and 23% (15–30) more treatment failures on zonisamide 
at 2 years. The doses taken at treatment failure or last 
follow-up and indicate that reasonable dose ranges were 
tried before deciding failure had occurred (appendix 3 p 7).
The competing risks analysis (appendix 3 p 8) shows 
that levetiracetam was significantly more likely to fail 
than lamotrigine because of adverse reactions (HR 0·53 
[95% CI 0·35–0·79]) but not inadequate seizure control 
(0·67 [0·45–1·01]). Similarly, zonisamide was signifi-
cantly more likely to fail than lamotrigine because of 
adverse reactions (0·37 [0·25–0·55]) but not because of 
inadequate seizure control (0·76 [0·50–1·15]).
SANAD II recorded data for adverse reactions, which 
were adverse events judged by the treating clinicians to 
be possibly, probably, or definitely caused by anti-seizure 
medication. Table 2 provides an ITT (by treatment policy) 
summary of adverse reactions according to the MEDRA 
system organ classification. Participants were included 
in the safety analysis if they took at least one dose of their 
allocated treatment.
There were 251 adverse reactions experienced by 
108 (33%) participants who initiated treatment with 
lamotrigine, 328 adverse reactions experienced by 
144 (44%) participants who initiated treatment with 
levetiracetam, and 351 adverse reactions in 146 (45%) 
participants who initiated treatment with zonisamide. 
The main difference in adverse reaction profiles was in 
reporting of psychiatric symptoms: 43 (13%) participants 
who initi ated lamotrigine, 98 (30%) participants who 
initiated levetiracetam, and 73 (23%) participants who 
initiated zonisamide.
Seven events were classified as a serious adverse 
reaction in two participants who initiated lamotrigine, 
one participant who initiated levetiracetam, four 
participants who initiated zonisamide, and none were 
suspected unexpected serious adverse reactions. There 
were 37 deaths during the trial; 15 in participants who 
initiated lamotrigine (four possibly seizure related), 12 in 
participants who initiated levetiracetam (two possibly 
seizure related), and ten in participants who initiated 
zonisamide (two possibly seizure related).
Figure 2: Kaplan-Meier plot of time to 12-month remission: lamotrigine versus levetiracetam and lamotrigine 




























































































HR lamotrigine vs levetiracetam 1·18 (0·95–1·47)
HR lamotrigine vs zonisamide 1·03 (0·83–1·28)





























































































HR lamotrigine vs levetiracetam 0·59 (0·46–0·77)
HR lamotrigine vs zonisamide 0·46 (0·36–0·59)
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There were 11 pregnancies in 11 women who initiated 
treatment with lamotrigine (ten with normal postnatal 
examination of the baby and one with minor malfor-
mations); six pregnancies in five women who initiated 
levetiracetam (five women with normal postnatal exami-
nation of the baby and one termination); 17 pregnancies 
in 14 women who initiated treatment with zonisamide; 
eight with normal postnatal examination of the baby; 
eight miscarriages (in five women) and one termination.
493 (49·8%) of participants returned QOL ques-
tionnaires at baseline and at least one other timepoint 
during follow-up. For participants who provided data 
for QOL, the mean follow-up time was 934 days (SD 519) 
and the maximum was 2289 days. A comparison of 
participants who did and did not return questionnaires 
showed a similar proportion of male and female partici-
pants and a similar proportion with learning disability 
and neurological deficits, although participants who 
returned the questionnaires were a mean of 10 years older 
(appendix 3 p 9).
Overall for adults, lamotrigine was associated with a 
better profile on self-reported measures than levetiracetam 
or zonisamide. A comparison of the treatment effects 
(appendix 3 p 10) showed negative treatment effects for 
levetiracetam compared with lamotrigine for patient 
reported anxiety, depression, stigma, epilepsy impact, and 
overall QOL. Compared with lamotrigine, zonisamide 
had a negative treatment effect for depression, epilepsy 
impact, and overall QOL.
Data for hospital episode statistics were available for 
772 participants, and self-reported resource-use data were 
available for 550 participants at 3 months, 527 partici pants 
at 6 months, 465 participants at 12 months, and 
398 participants at 24 months. Most of the costs were 
related to hospital outpatient clinic attendance and 
admitted care (appendix 3 p 11). In the adjusted, base-
case analysis, total costs were £4042 (97·5% CR 
3626–4983) for lamotrigine, £5104 (4450–6141) for 
levetiracetam, and £5400 (4659–6770) for zonisamide 
(table 3). EQ-5D utilities were available for 616 par-
ticipants at baseline, and they were calculated for 
422 participants at 12 months and for 319 participants 
at 24 months. Lamotrigine was asso ciated with 
1·605 QALYs (97·5% CR 1·547–1·651) in the base-case 
analysis, compared with 1·474 QALYs (1·393–1·523) 
with levetiracetam, and 1·502 QALYs (1·418–1·566) 
with zonisamide. At a cost-effectiveness threshold of 
£20 000 per QALY, net health benefits were higher, at 
1·403 QALYs (1·319–1·458) for lamotrigine, than for 
levetiracetam 1·222 (1·110–1·283), and for zonisamide 
1·232 (1·112–1·307). Lamotrigine therefore dominated 
both levetiracetam and zonisamide in the base-case 
analysis, and it had a probability of 0·999 of being cost-
effective at this threshold. Lamotrigine also dominated 
levetiracetam and zonisamide across all sensi tivity analyses 
(with the exception of the analysis of complete cases) and 
in the subgroup analysis of adults (table 3). However, 
levetiracetam had the highest net health benefit in 
Number of events Number of patients (%)
Lamotrigine Levetiracetam Zonisamide Lamotrigine (n=328) Levetiracetam (n=330) Zonisamide (n=324)
Psychiatric disorders 58 147 103 43 (13%) 98 (30%) 73 (23%)
Nervous system disorders 88 81 85 53 (16%) 55 (17%) 60 (19%)
General disorders and administration site conditions* 23 37 44 17 (5%) 32 (10%) 39 (12%)
Gastrointestinal disorders 30 29 35 25 (8%) 22 (7%) 26 (8%)
Skin and subcutaneous tissue disorders† 29 14 28 24 (7%) 12 (4%) 21 (7%)
Investigations 6 11 16 6 (2%) 11 (3%) 16 (5%)
Metabolism and nutrition disorders 4 2 17 3 (1%) 2 (1%) 16 (5%)
Musculoskeletal and connective tissue disorders 5 1 8 5 (2%) 1 (<1%) 7 (2%)
Eye disorders 1 1 5 1 (<1%) 1 (<1%) 5 (2%)
Renal and urinary disorders 1 0 6 1 (<1%) 0 5 (2%)
Cardiac disorders 2 2 1 2 (<1%) 2 (1%) 1 (<1%)
Respiratory, thoracic, and mediastinal disorders 1 1 2 1 (<1%) 1 (<1%) 2 (1%)
Injury, poisoning, and procedural complications 2 0 0 2 (1%) 0 0
Ear and labyrinth disorders 0 1 0 0 1 (<1%) 0
Endocrine disorders 0 1 0 0 1 (<1%) 0
Pregnancy, puerperium, and perinatal conditions 0 0 1 0 0 1 (<1%)
Vascular disorders 1 0 0 1 (<1%) 0 0
Total events and patients with at least one adverse 
reaction
251 328 351 108 (33%) 144 (44%) 146 (45%)
*88 (85%) of 104 adverse reactions in this category were fatigue. †42 events were rash: 22 events in the lamotrigine group, eight events in the levetiracetam group, and 12 events in the zonisamide group. 
Two of these were categorised as severe: one dermatitis allergic in the lamotrigine group and one Stevens Johnson syndrome in the levetiracetam group.
Table 2: Adverse reactions by MedDRA system organ classification
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participants younger than 16 years. Sensitivity analyses 
are provided in appendix 4 (pp 29–32).
Discussion
Our results indicate that lamotrigine should remain a 
first-line standard treatment for patients with focal 
epilepsy and that neither levetiracetam or zonisamide 
should be used routinely as first-line anti-seizure 
medications. This pragmatic multicentre randomised 
open-label trial was powered to assess non-inferiority of 
levetiracetam and zonisamide compared with the standard 
treatment lamotrigine in patients with newly diagnosed 
focal epilepsy. Zonisamide met our definition of non-
inferiority for the primary outcome time to 12-month 
remission (ITT analysis) compared with lamotrigine but 
levetiracetam did not, as the possibility of a clinically 
important differences could not be excluded. No signifi-
cant difference was found between lamotrigine and 
zonisamide for time to 24-month remission and time to 
first seizure. However, levetiracetam and zonisamide were 
significantly more likely to fail than lamotrigine and a 
competing risk analysis indicated that this treatment 
failure was due mainly to adverse reactions associated 
with levetiracetam and zonisamide. The PP analysis of 
time to 12-month remission, which accounted for 
treatment failure, found lamotrigine to be superior to both 
levetiracetam and zonisamide.
Initiating treatment with lamotrigine was associated 
with fewer adverse reactions than levetiracetam or 
zonisamide and there were more psychiatric adverse 
reactions associated with levetiracetam and zonisamide. 
Although there were 37 deaths, there was no indication 
of a higher death rate with a particular drug, which is 
reassuring given the concerns reported by the US Food 
and Drug Association, including cardiac rhythm and 
conduction abnormalities.27 Also, there were more 
pregnancies and miscarriages for patients who initiated 
zonisamide, but the numbers are too small to draw any 
conclusions.
QOL analyses found that, compared with lamotrigine, 
levetiracetam and zonisamide were associated with 
worse overall patient reported QOL and depression. In 
addition, levetiracetam was worse for patient reported 
anxiety, depression, and stigma.
The cost utility analysis found that neither levetiracetam 
or zonisamide were cost-effective compared with 
lamotrigine at thresholds of cost-effectiveness operating 
in the NHS in the UK. This finding was consistent in 
sensitivity analyses, and for the subgroup analysis of 
adults. However, levetiracetam appeared most cost-
effective in children who were younger than 16 years, 
although these results are limited by the small sample 
size and were principally due to a single participant who 
had an atypical medical journey.
This study has several limitations. Data for the 
occurrence of seizures were collected using seizure 
diaries and reports at clinic visits. It is therefore possible 
that seizures were missed or not reported, which might 
have influenced decisions about dose and treatment 
changes, treatment failure, and reporting of adverse 
reactions. Only 177 (17·9%) of patients recruited were 
younger than 18 years, limiting the applicability of our 
results to children. The most likely explanation for the 
small number of patients from this age group was 
because of lack of experience with zonisamide among 
paediatricians as it is not currently licensed as mono-
therapy in children. It is possible that the maintenance 
doses chosen introduced a systematic bias, but the 
similar time to first seizure rates for lamotrigine, 
levetiracetam, and zonisamide provide assurance against 
this possibility, as well as concerns that the slower 
titration rate required for lamotrigine could expose 
individuals to a risk of early seizure recurrence. It is 
also important to acknowledge that there are no data 
from randomised trials to inform the choice of 
initial maintenance dose of lamotrigine, levetiracetam, 
zonisamide, or most other anti-seizure medications, and 
that in SANAD II, clinicians chose and adjusted doses 
according to their usual practice. There was also a low 
return rate for QOL questionnaires and although the 
rates of return were not unusually low for postal 
questionnaires, this factor will have diminished our 
ability to identify differences in QOL between groups. 
A further limitation of our study was that other newer 
anti-epileptic drugs were not assessed, in particular 
lacosamide, which is now licensed as monotherapy for 
both adults and children, and perampanel, which is only 
licenced as an adjunctive therapy.
The economic analysis in our study was also limited 
by the poor return of participants’ questionnaires, the 
inclusion of free-text questions within the resource-use 
Lamotrigine Levetiracetam Zonisamide
Base-case all participants (n=990)
Total costs (£) 4042 (3626–4983) 5104 (4450–6141) 5400 (4659–6770)
QALYs 1·605 (1·547–1·651) 1·474 (1·393–1·523) 1·502 (1·418–1·566)
Net health benefit at 
£20 000 per QALY 
(QALYs)
1·403 (1·319–1·458) 1·222 (1·110–1·283) 1·232 (1·112–1·307)
Children aged <16 years (n=155)
Total costs (£) 5076 (3815–7219) 4972 (3739–6840) 4638 (3826–6974)
QALYs 1·551 (1·432–1·638) 1·556 (1·397–1·618) 1·508 (1·381–1·610)
Net health benefit at 
£20 000 per QALY 
(QALYs)
1·297 (1·127–1·412) 1·307 (1·097–1·394) 1·277 (1·068–1·390)
Adults and adolescents aged ≥16 years (n=835)
Total costs (£) 3844 (3379–4478) 5178 (4435–6223) 5509 (4610–6866)
QALYs 1·612 (1·554–1·661) 1·466 (1·381–1·518) 1·508 (1·412–1·569)
Net health benefit at 
£20 000 per QALY 
(QALYs)
1·420 (1·346–1·475) 1·207 (1·095–1·280) 1·227 (1·101–1·320)
Data are mean (97·5% central range). QALY=quality-adjusted life-years.
Table 3: Results of the adjusted base-case and subgroup analyses
See Online for appendix 4
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questionnaire, and the assumption that unanswered 
questions implied no use of resources. However, these 
limitations were largely mitigated by more complete 
data for hospital episode statistics given that hospital 
costs were the main cost driver and were associated 
with the more complex recall requirement. The effect of 
missing QALY data was lessened because of the area 
under the curve methodology, in which QALYs could be 
calculated provided two or more EQ-5D questionnaires 
had been returned. Our use of the EQ-5D-3L-Y and 
proxy version of the EQ-5D-3L was limited by the 
unavailability of appropriate value sets and by having to 
apply the adult tariff for estimating utilities. These 
factors represent a weakness in many economic 
evaluations of interventions in paediatric populations,22 
although a valuation of children’s EQ-5D-3L-Y health 
states is in development.28
These results should be interpreted in context with 
previous studies, although most anti-seizure monotherapy 
randomised controlled trials have been done to meet 
regulatory requirements29,30 and fail to provide evidence 
about longer term clinical effectiveness. SANAD I iden-
tified lamotrigine as a first-line treatment as it was 
non-inferior to carbamazepine for time to 12-month 
remission and superior to carbamazepine, gabapentin, 
oxcarbazepine, and topiramate for time to treatment 
failure.10 An indivi dual patient data network meta-
analysis,31 which included data from SANAD I and 
combined direct and indirect comparisons, used 
carbamazepine as the standard treatment comparator 
for patients with focal epilepsy. Results indicated that 
levetiracetam was inferior to carbamazepine for time to 
12-month remission and no significant difference was 
found for carbamazepine compared with gabapentin, 
lamotrigine, phenobarbital, phenytoin, oxcarbazepine, 
valproate, or zonisamide. For time to treatment failure, 
lamotrigine and levetiracetam were superior to carba-
mazepine, phenobarbital was inferior to carbamazepine, 
and no difference was found between carbamazepine 
and the other assessed treatments. SANAD II therefore 
provides much needed longer-term head-to-head data to 
better inform treatment policy and guidance.
Results from SANAD II have impor tant implications 
for clinical practice and research. Although levetiracetam 
and zonisamide are licensed for used as monotherapy in 
patients with focal epilepsy in Europe and worldwide, 
our results do not support their use as first-line mono-
therapy. This finding is most relevant to levetiracetam, 
which has become a commonly prescribed first-line anti-
seizure medication because of its ease of titration and 
assumed efficacy and tolerability. Further studies are 
now required to assess the clinical effectiveness and 
cost-effectiveness of other anti-seizure medications (eg, 
lacosamide, brivaracetam, and perampanel) and the 
design of future studies should be debated given that 
the SANAD I and SANAD II trials provide historical 
control data.
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